The deletion mutant EGFRvIII significantly contributes to stress resistance typical for the tumour microenvironment.

J. Theys, B. Jutten, L.J. Dubois, K.M.A. Rouschop, R.K. Chiu, Y. Li, K. Paesmans, P. Lambin, G. Lammering, B.G. Wouters

    Research output: Contribution to journalArticleAcademicpeer-review

    Abstract

    BACKGROUND AND PURPOSE: The epidermal growth factor receptor (EGFR) is overexpressed or mutated in many tumour types. The truncated, constitutively active EGFRvIII variant has not been detected in normal tissues but is found in many malignancies. In the current study, we have investigated the hypothesis that EGFRvIII contributes to a growth and survival advantage under tumour microenvironment-related stress conditions. MATERIALS AND METHODS: U373MG doxycycline-regulated isogenic cells expressing EGFRwt or EGFRvIII were created and validated using Western blot, FACS and qRT-PCR. In vitro proliferation was evaluated with standard growth assays. Cell survival was assayed using clonogenic survival. Animal experiments were performed using NMRI-nu-xenografted mice. RESULTS: Inducible isogenic cell lines were created and showed high induction of EGFRwt and EGFRvIII upon doxycycline addition. Overexpression of EGFRvIII but not of EGFRwt in this model resulted in a growth and survival advantage upon different tumour microenvironment-related stress conditions in vitro. Induction of EGFRvIII increased tumour growth in vivo, which was reversible upon loss of expression. CONCLUSIONS: Under conditions where nutrients are limited and stress is apparent, as in the tumour microenvironment, expression of EGFRvIII leads to a growth and survival advantage. These data indicate a potential selection of EGFRvIII-expressing tumour cells under such stress conditions.
    Original languageEnglish
    Pages (from-to)399-404
    JournalRadiotherapy and Oncology
    Volume92
    Issue number3
    DOIs
    Publication statusPublished - 1 Jan 2009

    Cite this